natgillin/translations-raw huggingface dataset:
High sperm DNA damage (sperm nuclear decondensation index and DNA fragmentation index) is a risk factor for male subfertility/infertility.
Velika poškodovanost DNK semenčic (indeks dekondenzacije semenčičnega jedra in indeks fragmentacije DNK) je dejavnik tveganja za zmanjšano plodnost/neplodnost pri moških.
Sugar-free hard confectionery with at least 90 % erythritol
Trdi konditorski izdelki brez sladkorja z najmanj 90 % eritritola
Sugar-free hard confectionery sweetened with at least 90 % Zerose® erythritol has been shown to reduce dental plaque.
Trdi konditorski izdelki brez sladkorja, sladkani z najmanj 90 % eritritola Zerose®, dokazano zmanjšujejo zobne obloge.
High content/level of dental plaque is a risk factor in the development of caries.
Velik obseg/delež zobnih oblog je dejavnik tveganja za razvoj kariesa.
Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods, and in particular Article 18(5) thereof,
ob upoštevanju Uredbe (ES) št. 1924/2006 Evropskega parlamenta in Sveta z dne 20. decembra 2006 o prehranskih in zdravstvenih trditvah na živilih ter zlasti člena 18(5) Uredbe,
Following an application from Laboratoires Nutrition et Cardiométabolisme, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Stablor®, a drink preparation with defined macro- and micronutrient composition and specific proportion of amino acids (tryptophan to neutral amino acids ratio) and decrease in visceral fat while preserving lean mass (Question No EFSA- Q-2016-00319).
Družba Laboratoires Nutrition et Cardiométabolisme je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Stablor®, pripravkom za napitek z določeno sestavo makro- in mikrohranil ter posebnim deležem aminokislin (razmerje med triptofanom in nevtralnimi aminokislinami) ter z zmanjšanjem trebušne maščobe in hkratnim vzdrževanjem puste telesne mase (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘In the context of a well-balanced diet and a mild caloric restriction, the addition of Stablor® contributes to decrease visceral fat while preserving lean mass in overweight or obese subjects with abdominal fat and cardiometabolic risk factors’.
EFSA-Q-2016-00319).
On 28 February 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Stablor® and reduction of visceral fat while maintaining lean body mass in the context of an energy restricted diet.
Vlagatelj je predlagal naslednjo trditev: „Ob uravnoteženi prehrani in nekoliko omejenem vnosu kalorij Stablor® prispeva k zmanjšanju trebušne maščobe in hkrati vzdržuje pusto telesno maso pri ljudeh s prekomerno težo ali debelostjo, pri katerih obstajajo dejavniki tveganja za srčno-žilne in presnovne bolezni.“
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
Komisija in države članice so 28. februarja 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka Stablor® ter zmanjšanjem trebušne maščobe in hkratnim vzdrževanjem puste telesne mase ob energijsko omejeni prehrani ni utemeljena.
Following an application from Suomen Terveysravinto Oy, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to curcumin and normal functioning of joints (Question No EFSA- Q-2016-00856).
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The claim proposed by the applicant was worded as follows: ‘Curcumin contributes to the normal functioning of joints’.
Družba Suomen Terveysravinto Oy je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi s kurkuminom in normalnim delovanjem sklepov (vprašanje št.
On 8 May 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of curcumin and the maintenance of joint function.
EFSA-Q-2016-00856).
Following an application from Marks and Spencer PLC, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to a carbohydrate:protein (CHO:P) ratio ≤ 1.8 on an energy basis in the context of an energy-restricted diet and body weight (Question No EFSA-Q-2016-00436).
Vložnik je predlagal naslednjo trditev: „Kurkumin prispeva k normalnemu delovanju sklepov.“
The claim proposed by the applicant was worded as follows: ‘Helps to achieve a reduction in body weight and body fat when consumed as part of an energy restricted diet (< 8,368 kJ/2,000 kcal/day) for a minimum of 12 weeks’.
Komisija in države članice so 8. maja 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kurkumina in vzdrževanjem normalnega delovanja sklepov ni utemeljena.
On 13 June 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of a CHO:P ratio ≤ 1.8 on an energy basis consumed in the context of an energy-restricted diet and the reduction of body weight.
Družba Marks and Spencer PLC je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z razmerjem med ogljikovimi hidrati in beljakovinami (CHO:P) ≤ 1,8 na podlagi energijske vrednosti v okviru energijsko omejene prehrane in zmanjšanja telesne teže (vprašanje št.
Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and reduction of body weight in the context of an energy-restricted diet (Question No EFSA- Q-2017-00032).
EFSA-Q-2016-00436).
The claim proposed by the applicant was worded as follows: ‘In the context of an energy-restricted diet contributes to weight loss’.
Vložnik je predlagal naslednjo trditev: „Pripomore k zmanjšanju telesne teže in telesne maščobe, če se v okviru energijsko omejene prehrane (< 8368 kJ/2000 kcal/dan) uživa najmanj 12 tednov.“
On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the reduction of body weight in the context of an energy-restricted diet.
Komisija in države članice so 13. junija 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka z razmerjem (CHO:P) ≤ 1,8 na podlagi vnosa kalorij v okviru energijsko omejene prehrane in zmanjšanja telesne teže ni utemeljena.
Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and maintenance of long-term normal blood glucose concentration (Question No EFSA- Q-2017-00033).
Družba Loc Troi group je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Vibigaba (kaljeni rjavi riž) in zmanjšanjem telesne teže ob energijsko omejeni prehrani (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Contributes to the maintenance of normal blood glucose levels’.
EFSA-Q-2017-00032).
On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the maintenance of long-term normal blood glucose concentration.
Vložnik je predlagal naslednjo trditev: „Ob energijsko omejeni prehrani prispeva k zmanjšanju telesne teže.“
Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood pressure (Question No EFSA- Q-2017-00031).
Komisija in države članice so 21. julija 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka Vibigaba (kaljeni rjavi riž) in zmanjšanjem telesne teže ob energijsko omejeni prehrani ni utemeljena.
The claim proposed by the applicant was worded as follows: ‘Contributes to the maintenance of normal blood pressure’.
Družba Loc Troi group je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Vibigaba (kaljeni rjavi riž) in dolgoročnim vzdrževanjem normalne ravni krvnega sladkorja (vprašanje št.
On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and the maintenance of normal BP.
EFSA-Q-2017-00033).
Following an application from Loc Troi group, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to Vibigaba (germinated brown rice) and contribution to the maintenance of normal blood cholesterol concentration (Question No EFSA- Q-2017-00030).
Vložnik je predlagal naslednjo trditev: „Prispeva k vzdrževanju normalne ravni krvnega sladkorja.“
The claim proposed by the applicant was worded as follows: ‘Contributes to the maintenance of normal blood cholesterol levels’.
Komisija in države članice so 21. julija 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka Vibigaba (kaljeni rjavi riž) in dolgoročnim vzdrževanjem normalne ravni krvnega sladkorja ni utemeljena.
On 21 July 2017, the Commission and the Member States received the scientific opinion from the Authority, which concluded that, on the basis of the data presented, a cause and effect relationship has not been established between the consumption of Vibigaba (germinated brown rice) and maintenance of normal blood cholesterol concentration.
Družba Loc Troi group je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Vibigaba (kaljeni rjavi riž) in vzdrževanjem normalnega krvnega tlaka (vprašanje št.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
EFSA-Q-2017-00031).
HAS ADOPTED THIS REGULATION:
Vložnik je predlagal naslednjo trditev: „Prispeva k vzdrževanju normalnega krvnega tlaka.“
Article 1
Komisija in države članice so 21. julija 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka Vibigaba (kaljeni rjavi riž) in vzdrževanjem normalnega krvnega tlaka ni utemeljena.
The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Družba Loc Troi group je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 predložila vlogo, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z izdelkom Vibigaba (kaljeni rjavi riž) in vzdrževanjem normalne ravni holesterola v krvi (vprašanje št.
Article 2
EFSA-Q-2017-00030).
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Vložnik je predlagal naslednjo trditev: „Prispeva k vzdrževanju normalne ravni holesterola v krvi.“
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Komisija in države članice so 21. julija 2017 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem izdelka Vibigaba (kaljeni rjavi riž) in vzdrževanjem normalne ravni holesterola v krvi ni utemeljena.
Done at Brussels, 17 October 2018.
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za rastline, živali, hrano in krmo –
OJ L 404, 30.12.2006, p. 9.
Zdravstvene trditve iz Priloge k tej uredbi se ne uvrstijo na seznam dovoljenih trditev Unije v skladu s členom 13(3) Uredbe (ES) št. 1924/2006.
Stablor®, a drink preparation with defined macro- and micronutrient composition and specific proportion of amino acids (tryptophan to neutral amino acids ratio)
Stablor®, pripravek za napitek z določeno sestavo makro- in mikrohranil ter posebnim deležem aminokislin (razmerje med triptofanom in nevtralnimi aminokislinami)
In the context of a well-balanced diet and a mild caloric restriction, the addition of Stablor® contributes to decrease visceral fat while preserving lean mass in overweight or obese subjects with abdominal fat and cardiometabolic risk factors.
Ob uravnoteženi prehrani in nekoliko omejenem vnosu kalorij Stablor® prispeva k zmanjšanju trebušne maščobe in hkrati vzdržuje pusto telesno maso pri ljudeh s prekomerno težo ali debelostjo, pri katerih obstaja tveganje za srčno-žilne in presnovne bolezni.
Curcumin contributes to the normal functioning of joints.
Kurkumin prispeva k normalnemu delovanju sklepov.
A carbohydrate:protein (CHO:P) ratio ≤ 1.8 on an energy basis in the context of an energy-restricted diet and body weight
Razmerje med ogljikovimi hidrati in beljakovinami (CHO:P) ≤ 1,8 na podlagi vnosa kalorij v okviru energijsko omejene prehrane in zmanjšanja telesne teže
Helps to achieve a reduction in body weight and body fat when consumed as part of an energy restricted diet (< 8368 kJ/2000 kcal/day) for a minimum of 12 weeks.
Pripomore k zmanjšanju telesne teže in telesne maščobe, če se v okviru energijsko omejene prehrane (< 8368 kJ/2000 kcal/dan) uživa najmanj 12 tednov.
Vibigaba (germinated brown rice)
Vibigaba (kaljeni rjavi riž)
In the context of an energy-restricted diet contributes to weight loss.
Ob energijsko omejeni prehrani prispeva k zmanjšanju telesne teže.
Contributes to the maintenance of normal blood glucose levels.
Prispeva k vzdrževanju normalne ravni krvnega sladkorja.
Contributes to the maintenance of normal blood pressure.
Prispeva k vzdrževanju normalnega krvnega tlaka.
Contributes to the maintenance of normal blood cholesterol levels.
Prispeva k vzdrževanju normalne ravni holesterola v krvi.
Commission Implementing Regulation (EU) 2018/1557
Izvedbena uredba Komisije (EU) 2018/1557
Having regard to Regulation (EU) 2016/1011 of the European Parliament and of the Council of 8 June 2016 on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investments funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014, and in particular Article 20(1), thereof,
ob upoštevanju Uredbe (EU) 2016/1011 Evropskega parlamenta in Sveta z dne 8. junija 2016 o indeksih, ki se uporabljajo kot referenčne vrednosti v finančnih instrumentih in finančnih pogodbah ali za merjenje uspešnosti investicijskih skladov, in spremembi direktiv 2008/48/ES in 2014/17/EU ter Uredbe (EU) št. 596/2014 in zlasti člena 20(1) Uredbe,
Commission Implementing Regulation (EU) 2016/1368 established a list of critical benchmarks used in financial markets pursuant to Regulation (EU) 2016/1011.
Z Izvedbeno uredbo Komisije (EU) 2016/1368 je bil določen seznam ključnih referenčnih vrednosti, ki se uporabljajo na finančnih trgih v skladu z Uredbo (EU) 2016/1011.
Pursuant to Article 20(1) of Regulation (EU) 2016/1011, the Commission is empowered to adopt implementing acts to establish and review at least every two years a list of critical benchmarks.
V skladu s členom 20(1) Uredbe (EU) 2016/1011 je Komisija pooblaščena za sprejetje izvedbenih aktov, da določi in vsaj vsaki dve leti pregleda seznam ključnih referenčnih vrednosti.
In accordance with point (b) of Article 20(1) of Regulation (EU) 2016/1011, benchmarks may be included in the list of critical benchmarks where those benchmarks, inter alia, are submitted by contributors the majority of which are located in one Member State and are recognised as being critical in that Member State.
V skladu s točko (b) člena 20(1) Uredbe (EU) 2016/1011 se na seznam ključnih referenčnih vrednosti lahko vključijo referenčne vrednosti, če te referenčne vrednosti, med drugim, predložijo prispevajoče osebe, katerih večina ima sedež v eni državi članici in ki se priznavajo za ključne v tej državi članici.
On 22 January 2018, the Swedish competent authority (‘Finansinspektionen’) notified the European Securities and Markets Authority (‘ESMA’) of its proposal to recognise the Stockholm Interbank Offered Rate (‘STIBOR’) as a critical benchmark, under point (b) of Article 20(1) of Regulation (EU) 2016/1011, because it is critical in Sweden and it is based on submissions of contributors, the majority of which are located in Sweden.
Švedski pristojni organ (Finansinspektionen) je 22. januarja 2018 obvestil Evropski organ za vrednostne papirje in trge (ESMA) o svojem predlogu, da se Stockholmska medbančna obrestna mera (STIBOR) prizna kot ključna referenčna vrednost v skladu s točko (b) člena 20(1) Uredbe (EU) 2016/1011, ker je ključna na Švedskem in temelji na predloženih podatkih prispevajočih oseb, katerih večina ima sedež na Švedskem.
STIBOR is a reference rate based on an average of the interest rates at which a number of banks active on the Swedish money market are willing to lend unsecured funds to each other at different maturities.
STIBOR je referenčna mera, ki temelji na povprečju obrestnih mer, po katerih si je več bank, ki delujejo na švedskem denarnem trgu, pripravljenih medsebojno posojati nezavarovana sredstva z različnimi zapadlostmi.
On 22 January 2018, seven banks participated in the STIBOR panel, six of which were located in Sweden and one in Denmark.
Na dan 22. januarja 2018 je v odboru za STIBOR sodelovalo sedem bank, od tega jih je imelo šest sedež na Švedskem, ena pa na Danskem.
In its assessment submitted to ESMA, Finansinspektionen concluded that the cessation of STIBOR, or its provision on the basis of input data or of a panel of contributors no longer representative of the underlying market or economic reality, could have a significant adverse impact on the functioning of financial markets in Sweden.
Finansinspektionen je v oceni, ki jo je predložil ESMA, prišel do sklepa, da bi prenehanje referenčne mere STIBOR ali njenega zagotavljanja na podlagi vhodnih podatkov ali skupine prispevajočih oseb, ki ne predstavlja več dejanskega tržnega ali gospodarskega stanja, negativno vplivalo na delovanje finančnih trgov na Švedskem.
The assessment by Finansinspektionen illustrates that STIBOR is used as a reference in the pricing of over-the-counter (‘OTC’) interest rate derivatives denominated in Swedish krona (‘SEK’) for an outstanding notional amount of EUR 3500 billion.
Iz ocene Finansinspektionen je razvidno, da se STIBOR uporablja kot referenčna mera pri določanju cen obrestnih izvedenih finančnih instrumentov OTC, denominiranih v švedski kroni (SEK), z neodplačanim nominalnim zneskom v višini 3500 milijard EUR.
Close to one fourth of SEK-denominated bonds reference STIBOR and STIBOR is used in the pricing of 75 % of total loans to Swedish households and non-financial institutions.
Približno ena četrtina obveznic, denominiranih v SEK, se sklicuje na STIBOR, prav tako se STIBOR uporablja pri določanju cen 75 % vseh posojil švedskim gospodinjstvom in nefinančnim institucijam.
The total value of financial instruments and financial contracts referencing STIBOR is about eight times larger than the gross national product of Sweden.
Skupna vrednost finančnih instrumentov in finančnih pogodb, ki se sklicujejo na STIBOR, je približno osemkrat višja kot bruto nacionalni proizvod Švedske.
STIBOR is therefore of vital importance for financial stability and market integrity in Sweden.
STIBOR je torej ključnega pomena za finančno stabilnost in celovitost trga na Švedskem.
The assessment concluded that STIBOR's discontinuity or unreliability could have a significant adverse impact on the functioning of financial markets in Sweden and on companies and consumers because it is used in loans, consumer credits products and investment funds.
V oceni je bilo ugotovljeno, da bi imela prenehanje zagotavljanja ali nezanesljivost referenčne mere STIBOR precejšen negativen vpliv na delovanje finančnih trgov na Švedskem ter na podjetja in potrošnike, ker se uporablja pri posojilih, potrošniških kreditih in investicijskih skladih.
On 23 February 2018, ESMA sent the Commission its opinion setting out that Swedish Finansinspektion had taken into consideration all the elements and criteria included in Article 20(3) of Regulation (EU) 2016/1011 and that it had provided quantitative data to support the case for the recognition of STIBOR as a critical benchmark, as well as analytical reasoning highlighting the crucial role of STIBOR in the Swedish economy.
ESMA je 23. februarja 2018 Komisiji poslal mnenje, v katerem je navedel, da je švedski Finansinspektion upošteval vse elemente in merila iz člena 20(3) Uredbe (EU) 2016/1011 ter predložil kvantitativne podatke v podporo priznanju referenčne mere STIBOR za ključno referenčno vrednost, poleg tega pa je predložil tudi analitično obrazložitev, v kateri je poudaril bistveno vlogo mere STIBOR v švedskem gospodarstvu.
Implementing Regulation (EU) 2016/1368 should therefore be amended accordingly.
Izvedbeno uredbo (EU) 2016/1368 bi bilo zato treba ustrezno spremeniti.
In light of the crucial importance of STIBOR, its widespread use and its role in the allocation of capital in Sweden, this Regulation should enter into force as a matter of urgency.
Zaradi ključnega pomena referenčne mere STIBOR, njene razširjene uporabe in njene vloge pri razporejanju kapitala na Švedskem bi ta uredba morala začeti veljati čim prej.
Done at Brussels, 17 October 2018.
V Bruslju, 17. oktobra 2018
Commission Implementing Regulation (EU) 2016/1368 of 11 August 2016 establishing a list of critical benchmarks used in financial markets pursuant to Regulation (EU) 2016/1011 of the European Parliament and of the Council (OJ L 217, 12.8.2016, p. 1).
Izvedbena uredba Komisije (EU) 2016/1368 z dne 11. avgusta 2016 o določitvi seznama ključnih referenčnih vrednosti, ki se uporabljajo na finančnih trgih v skladu z Uredbo (EU) 2016/1011 Evropskega parlamenta in Sveta (UL L 217, 12.8.2016, str. 1).
Euro Overnight Index Average (EONIA®)
Povprečje indeksa transakcij čez noč v evrih (EONIA®)
London Interbank Offered Rate (LIBOR)
Londonska medbančna obrestna mera (LIBOR)
London, United Kingdom
London, Združeno kraljestvo
Stockholm Interbank Offered Rate (STIBOR)
Stockholmska medbančna obrestna mera (STIBOR)
Swedish Bankers' Association (Svenska Bankföreningen)
Švedsko združenje bančnikov (Svenska Bankföreningen)
Commission Implementing Regulation (EU) 2018/1558
Izvedbena uredba Komisije (EU) 2018/1558